Categories: DNANews

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company’s first quarter 2024 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

1 hour ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

1 hour ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

1 hour ago

Catalyst by Wellstar Launches Polysight, Bringing Real-Time AI to Healthcare Compliance

The startup was formed to address rising regulatory complexity in healthcare.ATLANTA, Dec. 17, 2025 /PRNewswire/…

1 hour ago

Rockbridge Growth Equity-backed ProSites Acquires GeniusVets, Creating a Comprehensive Veterinary Marketing Platform under its LifeLearn Brand

LifeLearn offers a full suite of website creation, digital marketing, client communications and education, and…

1 hour ago

CORRECTION: TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care

PHILADELPHIA, PA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…

1 hour ago